Measures of morbidity were used to address VTE risk.
This shift did not occur in all studies, and when data from the hypothesis generating Bristol study were excluded, the adjusted odds ratios for leukaemia became 1.06 (0.89–1.25) in the first analysis and 1.16 (0.97–1.39) when data on prophylaxis imputed from hospital policy and perinatal morbidity were used.
The use and type of complementary medications, elements of personal health profile (drug type, medication count, the absence versus presence of a chronic physical health condition, and psychiatric morbidity) were used as predictors, as were sample demographics (age, sex, ethnicity, marital status, education, and poverty index).
In addition to these factors, two types of health outcomes (mortality and morbidity) are used.
8-year prevalence of general and GI-specific morbidity was used as measure for the comparisons between cases and controls.
The terms "near miss" and "severe maternal morbidity" are used interchangeably, but severe maternal morbidity reflects a less serious condition and represent a situation that precedes near miss cases in severity [ 10].
Four of the studies used 1 g cefazolin and two used 2 g. 25, 29 In all the studies the primary outcome of maternal infectious morbidity was used for the power calculation.
An index of morbidity was used by assessing the absence of health problems, the occurrence of isolated risk factors (high blood pressure, high blood cholesterol, diabetes), the prevalence of moderate morbidities (various conditions), and of severe morbidities (cardiovascular diseases, heart failure, chronic obstructive pulmonary diseases).
Survival or survival with major morbidity was used as dependent factor, gestational age <26 weeks, birth weight <800 g, Apgar score ≤3 at 5 min, survival with at least one major morbidity, multiple pregnancy and cervical insufficiency were used as covariate factors in the model for total survival.
In this study, a postal questionnaire, including SF-36, demographics, lifestyle indicators, gastrointestinal and other co-morbidity were used.
The estimated effects obviously depend on which measures of co-morbidity were used and whether they were dichotomous 23, 44, 45 or ordinal categorical variables calculated from the number of pre-existing medical conditions.
